A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)

Read full text Summarise with VIRAT
Authors: Novartis
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine

Fields of Study & Subjects

Migraine and Headache Studies Pain Mechanisms and Treatments Intracranial Aneurysms: Treatment and Complications

Publication details

Journal / source
Vivli
Publication date
27 March 2026
Language
EN
Document type
Dataset